Improvement in the handling of drug-drug interactions.
Approximately one in 200 hospitalised patients has a serious adverse drug effect caused by drug-drug interactions (DDIs). Such adverse effects should be avoidable, but current information provided on DDIs is often incomplete and difficult or even impossible to translate into true risk and appropriate tangible action. Clinicians need to know the mean and maximal expected effect of a DDI on clinical endpoints, any dose adjustments required, and how to monitor tolerability and efficacy in patients subject to a DDI. To this end, improved study designs should take the objective of improving treatment explicitly into account, and any existing DDI data should be publicly accessible. Modelling needs to be used more extensively in order to quantitatively predict the effects of DDIs on clinical endpoints in patients and to relate clinical endpoint effects considered as acceptable to respective changes in experimental and clinical studies. Computer-based expert systems will be required to convert such DDI data into recommendations applicable to the individual patient. Therefore, the incorporation of DDIs in a more general procedure for personalisation of drug therapy is desirable.
Fuhr
Uwe
U
Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Köln, Germany. uwe.fuhr@uk-koeln.de
D004347:Drug Interactions; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D033181:Information Dissemination / Q000379:methods*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D010601:Pharmacology, Clinical; D012107:Research Design / Q000592:standards
D004364:Pharmaceutical Preparations